Your browser is no longer supported. Please, upgrade your browser.
EVOK Evoke Pharma, Inc. weekly Stock Chart
EVOK [NASD]
Evoke Pharma, Inc.
Index- P/E- EPS (ttm)-0.29 Insider Own1.10% Shs Outstand24.99M Perf Week20.00%
Market Cap124.46M Forward P/E- EPS next Y-0.13 Insider Trans0.00% Shs Float23.73M Perf Month42.15%
Income-7.00M PEG- EPS next Q-0.10 Inst Own12.90% Short Float3.70% Perf Quarter260.84%
Sales- P/S- EPS this Y29.90% Inst Trans-11.37% Short Ratio0.54 Perf Half Y260.84%
Book/sh-0.01 P/B- EPS next Y56.70% ROA- Target Price- Perf Year489.65%
Cash/sh0.33 P/C15.56 EPS next 5Y40.00% ROE- 52W Range0.73 - 6.06 Perf YTD218.52%
Dividend- P/FCF- EPS past 5Y32.00% ROI- 52W High-12.25% Beta1.94
Dividend %- Quick Ratio1.20 Sales past 5Y- Gross Margin- 52W Low625.56% ATR0.35
Employees5 Current Ratio1.20 Sales Q/Q- Oper. Margin- RSI (14)77.08 Volatility13.06% 7.79%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.20 Prev Close5.16
ShortableYes LT Debt/Eq- EarningsAug 06 BMO Payout- Avg Volume1.63M Price5.32
Recom2.00 SMA2034.20% SMA5054.92% SMA200180.04% Volume197,940 Change3.10%
Jun-22-20Upgrade H.C. Wainwright Neutral → Buy $10
Mar-05-19Downgrade H.C. Wainwright Buy → Neutral
Mar-08-18Reiterated B. Riley FBR, Inc. Buy $10 → $5
Oct-19-17Resumed FBR & Co. Buy $10
Mar-16-17Reiterated Rodman & Renshaw Buy $6 → $9
Jan-30-17Upgrade Laidlaw Neutral → Buy $8
Jan-05-17Upgrade Rodman & Renshaw Neutral → Buy $2.50 → $6
Dec-23-16Reiterated Rodman & Renshaw Neutral $2 → $2.50
Jul-19-16Reiterated FBR Capital Outperform $17 → $9
Jul-19-16Downgrade Noble Financial Buy → Hold
Jul-18-16Downgrade Rodman & Renshaw Buy → Neutral $2
Mar-16-16Initiated Northland Capital Outperform
Mar-14-16Reiterated Ascendiant Capital Markets Buy $11 → $12
Feb-17-16Resumed FBR Capital Outperform $17
Dec-03-14Reiterated MLV & Co Buy $12.50 → $14
Nov-07-14Initiated MLV & Co Buy $12.50
Apr-22-14Initiated Laidlaw Buy $19
Nov-19-13Initiated Aegis Capital Buy $60
Aug-06-20 08:30AM  
Jul-15-20 08:30AM  
Jul-08-20 08:30AM  
Jun-25-20 10:58PM  
Jun-22-20 10:23AM  
Jun-19-20 03:32PM  
May-20-20 08:30AM  
May-12-20 08:30AM  
Mar-12-20 08:30AM  
Jan-27-20 08:30AM  
Jan-23-20 08:30AM  
Jan-22-20 10:00AM  
Jan-21-20 08:30AM  
Dec-20-19 08:30AM  
Dec-02-19 08:30AM  
Nov-18-19 08:52AM  
Nov-13-19 08:30AM  
Nov-07-19 08:30AM  
Sep-20-19 05:14PM  
Sep-19-19 12:02PM  
10:29AM  
Sep-17-19 08:30AM  
Aug-08-19 05:30AM  
Jul-25-19 12:58PM  
Jul-11-19 11:31AM  
Jun-27-19 08:30AM  
May-08-19 04:05PM  
11:39AM  
Apr-29-19 09:13AM  
Apr-15-19 12:08PM  
Apr-03-19 08:19AM  
Apr-02-19 06:00AM  
Mar-29-19 12:45PM  
Mar-14-19 08:30AM  
Mar-06-19 08:30AM  
Mar-04-19 08:30AM  
Feb-27-19 08:30AM  
Jan-07-19 08:30AM  
Jan-04-19 07:56AM  
Nov-13-18 04:05PM  
Oct-16-18 10:32AM  
Oct-08-18 06:28PM  
Sep-28-18 09:59AM  
Aug-17-18 09:12AM  
Aug-16-18 08:30AM  
Aug-09-18 04:05PM  
Jun-06-18 01:38PM  
Jun-04-18 07:30AM  
May-14-18 10:27AM  
06:30AM  
May-10-18 07:30AM  
Apr-30-18 07:30AM  
Mar-26-18 07:30AM  
Mar-07-18 04:05PM  
12:00PM  
Mar-06-18 07:30AM  
Mar-05-18 07:30AM  
Feb-21-18 08:30AM  
Feb-15-18 07:30AM  
Dec-12-17 07:40AM  
Dec-11-17 07:30AM  
Nov-14-17 04:05PM  
12:00PM  
06:49AM  
Nov-09-17 08:30AM  
Nov-07-17 08:30AM  
06:33AM  
Oct-27-17 08:30AM  
Oct-23-17 07:30AM  
Oct-17-17 09:53AM  
Oct-04-17 08:30AM  
Sep-12-17 08:30AM  
Sep-05-17 08:30AM  
Aug-14-17 04:05PM  
12:10PM  
08:30AM  
Aug-07-17 08:30AM  
May-31-17 08:30AM  
May-15-17 04:05PM  
03:00PM  
May-10-17 08:30AM  
May-01-17 08:30AM  
Apr-18-17 08:30AM  
Apr-04-17 08:30AM  
08:30AM  
Mar-22-17 01:04PM  
Mar-21-17 08:30AM  
Mar-15-17 04:12PM  
04:05PM  
07:07AM  
Mar-10-17 05:19PM  
Mar-07-17 08:30AM  
Mar-06-17 08:30AM  
Feb-16-17 04:15PM  
09:30AM  
08:46AM  
Feb-15-17 04:42PM  
10:55AM  
10:55AM  
08:49AM  
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.